Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...

Abbott Laboratories raised its 2024 earnings guidance after strong Q3 results, driven by growth in Pharma and MedTech ...

Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street ...

On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street ...

Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read: ...

At its current valuation, DexCom stock is the opposite of a bargain. Even after its big drop over the summer, it would still be a risky stock to buy now. Those who are interested would probably do ...